Replies to post #492741 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine's Economic Advantages

A safe low-cost pill that has actually shown to save the brain from atrophy with no need for brain imaging could help save governments billions in Alzheimer's future-related medical costs.

Yes, important factors to consider. There is sound evidence that blarcamesine obviates or prevents brain atrophy, the process(es) whereby brain volume and mass shrinks, in both normal aging and with Alzheimer's disease, and with the current monoclonal antibody Alzheimer's drugs. The new, approved monoclonal antibody Alzheimer's drugs, because of the brain atrophy they generate, require periodic brain imagining, so that if atrophy is discovered the drugs can be withheld to prevent the lethal atrophy of the drug. Blarcamesine presents no such concerns. Brain volume is not jeopardized. No expenditures for radiological brain scans.

This is one important factor in Anavex's current petition for blarcamesine approval in Europe. In Europe brain scan technologies are far less common than in the U.S. In Europe, far more expensive and far more inconvenient to get a brain scan. An Alzheimer's drug not requiring brain scans has economic advantages.

The other important factor will be blarcamesine's production costs. The monoclonal antibody drugs are very expensive to produce. Individual doses are very expensive. On the other hand, blarcamesine is a rather small molecule for which Anavex has patents covering the synthesis of the drug. A fifty-milligram tablet should be made for less than a dollar; more likely in the range of 25 to 50 cents.

For these reasons blarcamesine economically out competes the existing Alzheimer's drugs; something the European Medicines Agency will be aware of.

[Bourbon_on_my_cornflakes]

A safe low-cost pill that has actually shown to save the brain from atrophy with no need for brain imaging could help save governments billions in Alzheimer's future-related medical costs. This is likely also being weighed out in the approval process.

Makes sense to me, but the professional bureaucrats here say saving money will have zero influence on approval. Given the way bureaucrats operate, that may be true.